Effective methods for decreasing pressure ulcer formation in older adults who spend a significant amount of time in a wheelchair include better nutrition, skin protection, and increasing patient mobility.
Statins Show Significant Promise in Patients With NAFLD

Safety and Efficacy of Long-Term Statin Treatment for Cardiovascular Events in Patients With Coronary Heart Disease and Abnormal Liver Tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A PostHoc Analysis.
Athyros VG, Tziomalos K, et al: Lancet 2010; 376 (December 4): 1916 376 (December 4): -1922 In patients with abnormal liver function tests likely secondary to nonalcoholic fatty liver disease, statins decrease mortality and improve liver function.
The End for PSA?
Screening for Prostate Cancer: Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Djulbegovic M, Beyth RJ, et al: BMJ 2010; 341 (September 14) : epub ahead of print Prostate-specific antigen screening for prostate cancer continues to struggle against evidence suggesting it is not effective in increasing survival.
Objective: To determine the best method of screening for prostate cancer.
Design/Methods: A systematic review was performed to include all randomized, controlled trials (RCTs) comparing prostate cancer screening with prostate-specific antigen (PSA) to no screening. Compatible results were also compiled in a meta-analysis.
Results: 6 individual RCTs have been done to date with 387,286 total patients. Screening was associated with a greater chance of being diagnosed with prostate cancer (RR, 1.46), especially stage 1 (RR, 1.95). However, screening was not associated with improved cancer-specific survival (RR, 0.88; 95% CI, 0.71 to 1.09; P =0.25) or overall survival (RR, 0.99; 95% CI, 0.97 to 1.01; P =0.44).
Conclusions:
The data from all RCTs of screening with PSA for prostate cancer reveals no survival benefit for screening. However, every study had at least one significant methodological flaw. In addition, information on quality of life effects, harms, and costs is lacking.
Reviewer's Comments: Djulbegovic and colleagues reported the results of their systematic review and metaanalysis of prostate cancer screening trials using PSA. In addition to 4 recent studies from the United States and Europe, they found 2 previous RCTs from Quebec and Sweden, which were included. The methodological quality of each individual study was critically assessed. In addition, the quality of evidence for each specific outcome was evaluated, using an international grading system known as "GRADE." The authors were able to demonstrate that the current quality of evidence for overall survival, for example, is "moderate," while evidence for the effects of screening specifically on stage II prostate cancer (arguably the stage in which we hope to make the most impact on the natural history of the disease) is "very low." The meta-analysis revealed a 46% relative increase in the diagnosis of prostate cancer from screening; most of these cases were stage I disease. For higher stages, there was no change in diagnosis with screening, although the quality of evidence was low. Finally, based on moderate quality evidence, there was no change in cancer-specific or overall mortality with screening. In fact, the 95% confidence intervals for overall mortality were incredibly narrow (0.97 to 1.01), suggesting that it may be hard to dispute this finding with future studies. There are arguments against these findings. It may be inappropriate to combine these studies in a meta-analysis due to methodological flaws that make them incompatible; follow-up may need to be longer; high-risk populations may need exploration; and other important outcomes may need consideration, such as metastatic disease and quality of life. What appears to be clear is that we sorely need a better test. We can't revert back to pre-PSA era. Therefore, we should be vigilant against overtreatment of patients, at least until a better test becomes available. (ReviewerSteven E. Canfield, MD). Cornu J-N, Cancel-Tassin G, et al: Eur Urol 2011; 59 (February): 197-201 Sensitivity and specificity are approximately 91% when a trained canine is utilized to detect prostate cancer.
Background: Volatile organic compounds in urine have been suggested as potential markers of cancer detection. Recently, a small study found that bladder cancer could be detected by a trained dog, so why not try a similar experiment with prostate cancer patients?
Objective: To evaluate the sensitivity and specificity of dogs trained to detect prostate cancer from urine samples of humans.
Methods:
A Belgian Malinois shepherd dog was trained for >2 years to scent and locate urine of men with prostate cancer. After this time, a double-blind procedure was utilized. Urine was used from 66 patients referred to a urologist for an elevated prostate-specific antigen or abnormal digital rectal examination (DRE). All patients had a biopsy; 33 patients had cancer and 33 were negative biopsy controls. During each "run," there were 5 samples without cancer and 1 sample with cancer (6 total). The dog had 1 chance to signal which of the samples were from a patient with cancer.
Results:
The dog detected the correct cancer sample in 30 of the 33 cases presented to it. Of 3 cases that the dog missed, 1 patient was rebiopsied and cancer was found. Sensitivity and specificity were both 91%.
Conclusions: Dogs can be trained to detect prostate cancer, but this study also suggests that specific compounds can be located in the urine and used as novel cancer detection agents.
Reviewer's Comments: Holy canine conundrum Batman! This is one small paw step for man and one giant leap for mankind. And I always thought that the only reason my dog buried himself in my clothing (notice the politically correct wording) when I came home from work was because he was looking for a doggy treat and not because he was looking for prostate cancer. Still, it is intriguing that dogs have been trained to detect explosives, drugs, and squirrels, so why not other compounds that can detect cancer or other diseases? There have been some preliminary studies already completed in individuals with bladder, breast, and lung cancer that have demonstrated the ability of some dogs to detect these tumors with a greater chance than just basic probability or luck. Behavioral therapies are a key component to achieving urine continence in patients who are incontinent after prostatectomy.
Background:
The use of behavioral therapies, biofeedback, and electrical stimulation of pelvic muscles has been shown to be useful in treating urine incontinence in the immediate postoperative period after prostatectomy in past studies. These methods of intervention in the setting of urine incontinence that persist past 1 year in postprostatectomy patients have not been previously analyzed.
Objective: To further assess the effectiveness of nonsurgical and non-medication interventions in the setting of postprostatectomy urine incontinence.
Design: Prospective, randomized, controlled trial.
Participants: 208 men participated in this study. They all suffered from postprostatectomy urine incontinence at least 1 year after surgery. Approximately 25% were African American, and 75% were white.
Methods: Outcomes were measured in the percent reduction of episodes of urine incontinence at 8 weeks as recorded in the weekly bladder diary. Questionnaires were also used to assess quality of life and measure possible changes in quality of life after 8 weeks of treatment. Patients were then seen at 6 months and 12 months.
Interventions: Participants were broken up into 3 groups: those who received only behavioral therapy; those who received behavioral therapy plus biofeedback and home electrical stimulation of pelvic muscles; and a delayed treatment group that served as a control group. Behavioral therapy included pelvic floor muscle contraction instruction, fluid management, and bladder diaries recording voiding, accidents, and the number of pelvic floor muscle exercises done. These diaries were reviewed and further instruction was given on bladder control strategies. Patients randomized to behavioral therapy plus biofeedback and electrical stimulation received similar teaching but with the addition of biofeedback during sessions of teaching on pelvic floor muscles and a home electrical stimulation unit and instruction and directions for its use. The control group just kept bladder diaries without any instruction.
Results: At 8 weeks, the behavioral therapy group had a mean reduction of 55% of incontinence episodes as compared to the control group. Those who received behavior therapy plus biofeedback and electrical stimulation had a 51% mean reduction of incontinence episodes. These improvements were sustained after 12 months. Ninety percent of the participants in the treatment groups described their symptoms as "better" or "much better" as compared to controls.
Conclusions:
Behavioral therapies for postprostatectomy urine incontinence are a key part of a treatment plan for a patient. The addition of electrical stimulation and biofeedback did not improve upon the results achieved by behavioral therapy. In children with uncomplicated otitis media and normal risk, only 12 in 100 benefit from antibiotics, and most antibiotics are equivalent in clinical success.
Only 12 in 100 Children With Uncomplicated Otitis Media Benefit From Antibiotics
Objective: To look at the precision and accuracy of acute otitis media diagnosis, to assess the effect of the pneumococcal vaccine in microbial epidemiology, to review the evidence about the decision to treat with antibiotics, and to examine the effectiveness and adverse events of various antibiotics.
Design/Methods: Systematic review of articles from 1999 to 2010 on otitis media, which is the most common reason for which antibiotics are prescribed for US children, although there is wide variation in diagnosis and treatment.
Results: Regarding diagnosis, the authors concede that the accuracy of clinical features is clouded by the lack of a consistent gold standard, such as tympanocentesis. Of parent-reported symptoms, ear pain and ear rubbing are only modestly associated with otitis media. Of otoscopic findings, a bulging eardrum was most closely associated with the diagnosis. Immobility on pneumatic otoscopy was also strongly associated with infection, but redness had a much lower correlation with the likelihood of acute otitis media. Since the pneumococcal vaccine, most studies have found that Haemophilus influenzae has become more prevalent as a middle ear isolate with Streptococcus pneumoniae less prevalent, although it has remained important, particularly the non-vaccine serotypes. The authors examined many studies that looked at the benefits of antibiotic treatment, the use of amoxicillin versus placebo, immediate versus delayed antibiotics, short-and long-term antibiotic harms, and comparative antibiotic effectiveness. Of 100 average-risk children with otitis media, 80% will get better within 3 days without antibiotics. Amoxicillin does improve the outcome. The authors estimated that if all 100 were treated with amoxicillin, an additional 12 would improve, but 3 to 10 would develop rash and 5 to 10 would develop diarrhea. It is these risks versus benefits, including long-term issues related to antibiotic resistance, that clinicians must weigh before deciding on therapy. When the authors looked at uncomplicated otitis cases in normal-risk children, they could find no evidence of the superiority of amoxicillin over any other antibiotic, including cefdinir, cefixime, and ceftriaxone.
Conclusions:
Otoscopic findings remain critical to accurate acute otitis media diagnosis. Since the introduction of the pneumococcal vaccine, microbiology of inner ear pathology has changed. Compared to no treatment, antibiotics are modestly effective but may cause adverse events in 4% to 10%. Most antibiotics are equivalent in clinical success.
More Intensive Statin Treatment Associated With Incremental Reductions in CV Risk
Efficacy In this meta-analysis, more intensive statin therapy resulted in greater reductions in major cardiovascular events than less intensive statin therapy. More intensive therapy also appeared to be safe.
Background: Trials that have specifically studied more intensive statin treatment have been suggestive of greater cardiovascular risk reduction compared with less intensive treatment, but several studies have had nonsignificant results.
Objective: To use individual specific data to evaluate the efficacy and safety of more intensive statin therapy.
Design/Methods:
This meta-analysis included trials of statin therapy that lasted at least 2 years and had at least 1000 participants. The primary outcome was major cardiovascular events over an average follow-up of 5.1 years. Analysis was performed by intention to treat. The effect size was reported by change in outcome per 1.0 mmol/L reduction in LDL cholesterol (1.0 mmol/L cholesterol = 38.67 mg/dL).
Results: A total of 5 studies comparing more intensive statin therapy to less intensive statin therapy were included, 2 with acute coronary syndromes (8659 patients) and 3 with stable coronary disease (30,953 patients). At baseline, the average LDL cholesterol was 2.53 mmol/L (97.8 mg/dL); it was reduced an average of 0.51 mmol/L (19.72 mg/dL). Subjects in the intensive treatment arms experienced major cardiovascular events at a lower rate than subjects in the less intensive treatment arms. The reduction in major cardiovascular events was 28% per 1.0 mmol/L reduction in LDL cholesterol (95% CI, 22 to 34; P <0.0001), similar to the reduction observed in a meta-analysis of statin versus placebo trials (21% per 1.0 mmol/L reduction in LDL cholesterol). Each of the constituent elements of the composite outcome was significantly reduced. There was a significant reduction in all strokes, but a nonsignificant increase in hemorrhagic strokes was associated with more intensive statin therapy. There was no increase in first cancers diagnosed among patients randomized to more intensive treatment. Rhabdomyolysis was rare, but there appeared to be an excess of rhabdomyolysis in patients treated with 80 mg of simvastatin compared to 20 mg.
Conclusions:
More intensive statin treatment resulted in further reductions in cardiovascular risk than less intensive treatment.
Reviewer's Comments:
This meta-analysis adds to our understanding of statin therapy, suggesting that more intensive therapy reduces cardiovascular risk more than less intensive therapy, to the tune of about a 20% relative reduction in risk for every 1.0 mmol/L (39 mg/dL) reduction in LDL cholesterol. More intensive therapy appeared safe, particularly when using more potent statins (atorvastatin or rosuvastatin) rather than higher doses of less potent statins. It remains essential to consider absolute cardiovascular risk when making clinical decisions about statin therapy, but this study supports the approach of more intensive lipid lowering in patients with the highest cardiovascular risk. (Reviewer-Paul R. Sutton, PhD, MD).
Keywords: Statin Therapy, Intensive Statin Therapy, Meta-Analysis β-blockers initiated >1 week before vascular surgery are more cardioprotective than therapy that is initiated <1 week before surgery.
Beta-Blockers Before Vascular Surgery --The Earlier, the Better
Timing of Pre-Operative Beta-Blocker Treatment in Vascular Surgery
Background: β-blockers have been demonstrated to have benefit in preventing perioperative cardiovascular complications. Among the mechanisms thought to contribute to the cardioprotective effect are alterations in sympathetic nervous system function and a decrease in inflammatory markers such as C-reactive protein (CRP) that may result in plaque stabilization. Although multiple studies have shown benefit to perioperative β-blockade, the timing of initiation has not been well defined.
Objective: To evaluate the timing of perioperative β-blockade initiation in a cohort of patients undergoing vascular surgery.
Participants/Methods: 940 patients undergoing vascular surgery, either open or endovascular, were evaluated. Exclusion criteria were heart rate <50 bpm, prior randomization to β-blocker treatment, or emergency surgery. β-blocker initiation was begun either <1 week, >1 week to 4 weeks, or >4 weeks before surgery. For patients in whom β-blockers were started >1 week before surgery, a second clinic visit 1 week after initiation of therapy was utilized to titrate dosing to ensure a resting heart rate of 60 to 70 bpm. The usual cardiovascular comorbidities were assessed, and CRP levels were drawn 1 day before surgery. The primary outcome was cardiovascular events within 30 days (myocardial infarction or ischemia, stroke, or death), with secondary outcomes of perioperative heart rate and CRP levels. Mean follow-up was 2.2 years.
Results: 70% of patients received bisoprolol, 20% received metoprolol, 5% received atenolol, and 5% received other β-blockers; 77% of patients were men, and the mean age was 67 years. Those receiving β-blockers >1 to 4 weeks and >4 weeks before surgery had a lower resting heart rate on the day of surgery than those who began therapy <1 week before surgery (70 and 66 vs 74 bpm). There was no difference in CRP levels the day before surgery. Of patients in the <1 week group, 27% had perioperative cardiovascular events compared with 15% of those whose therapy was initiated >1 to 4 weeks and >4 weeks preoperatively (HR, 0.46 and 0.48, respectively) . The majority of events were troponin release. The hazard ratios for long-term mortality for those with β-blocker initiated >1 to 4 weeks and >4 weeks compared to those with therapy begun at <1 week were 0.55 and 0.50, respectively. There is no significant risk of birth defects from proton pump inhibitor use in the first trimester.
PPIs in Early Pregnancy Do Not Increase Risk for Birth Defects
Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects.
Objective: To determine the risk of birth defects from pre-conception and first-trimester exposure to proton pump inhibitors (PPIs).
Methods:
In this study from Denmark, the authors used the national health registers to obtain data regarding birth, prescription, and potential confounders (patient history). A cohort of live infants was identified from 1996 to 2008. Women who were pregnant were identified. Prescriptions that were filled by these women for PPI medications between 4 weeks pre-conception up to 12 weeks post-conception were monitored. Birth defects from these pregnancies were documented.
Results:
The total study cohort included >840,000 births, including 32,000 multiple births. There were 2.6% who had identifiable birth defects. Omeprazole was the most common PPI prescribed. A total of 3.4% of mothers who used a PPI had major birth defects compared to 2.6% of the controlled cohort. Women who used a PPI in the first trimester had no significant risk for major birth defects. There was a slight increase of risk for those mothers who took a PPI within 4 weeks prior to conception. There was no significant risk with an individual PPI medication. Lansoprazole taken within 4 weeks before conception had an increased risk. Post hoc statistical analysis confirmed there was no significant risk for birth defects.
Conclusions:
There is no significant risk of birth defects from PPI used in the first trimester. Women who expect to become pregnant should consider discontinuing these PPIs if they are trying to conceive.
Reviewer's Comments: Women can be reassured that the PPIs have low risks for birth defects. The data showed that there is a slightly higher risk for those mothers who started the medication pre-conception. Since many PPIs are over the counter, these women need to be reminded to check with a doctor prior to taking any medications. For women who are trying to conceive, the avoidance of any non-essential medications, including PPI medications, can help reduce the risk of serious birth defects. (Reviewer-Charles I. Schwartz, MD).
Keywords: Birth Defects, Proton Pump Inhibitors
Infant Media Exposure Affects Toddler Development
Infant Media Exposure and Toddler Development. Increased media exposure in a 6-month-old child appears to be significantly associated with impaired cognitive and language development at 14 months of age.
Background: Despite recommendations that children have no more than 2 hours of media exposure per day, such exposure appears to be increasing overall. Studies show that children from families with a low socioeconomic status (SES) seem to have higher exposure than those from families with higher SES. Studies that link media exposure to adverse events and less optimal development have not been prospective or have focused on children from families with a higher SES.
Objective: To examine whether media exposure at 6 months of age is associated with development at 14 months of age.
Methods/Participants:
This was a study of mother-infant dyads in the Bellevue Project for Early Language, Literacy, and Education Success, a study that attempted to improve development with interventions to encourage shared reading and play. Total duration and content of media exposure were measured at 6 months of age. Media exposure was assessed using a 24-hour recall diary based on a maternal interview. Total duration was measured in minutes. Content was classified into the following categories: educational young child-oriented programs, noneducational young child-oriented programs, older child/adult-oriented programs, and unknown programs. At 14 months of age, cognitive development was measured using the Bayley Scales of Infant and Toddler Development, 3rd edition, Cognitive Scale. Language development was also assessed using the Preschool Language Scale-4. Demographic data and maternal health data were also collected for analyses.
Results:
Over the 26-month study period, 516 mother-infant dyads were enrolled in the study, and 377 had data collected at 6 months of age. Of these, 259 also had data collected at 14 months of age. Average media exposure at 6 months was 153 minutes a day; only 16% were exposed to <1 hour a day. Even after adjusting for confounding factors, increased media exposure was significantly associated with lower cognitive development (B = -0.15) and lower language development (B = -0.16). When broken down into categories of content, only older child/adult-oriented media was associated with lower development at 14 months of age.
Conclusions:
Increased media exposure in a 6-month-old child appears to be significantly associated with impaired cognitive and language development at 14 months of age.
Reviewer's Comments: This prospective study showed that increased media exposure in 6-month-old children is associated with decreased language and cognitive development 8 months later. This is troublesome, as the average amount of media exposure in a 6-month-old child was over 2.5 hours. It also seems that older-child/adult-oriented media is the most troublesome. Early exposure to large group child care leads to more infections for infants and preschoolers but fewer infections once they become school aged.
Objective: To determine whether the frequency of respiratory tract infections (RTIs) with fever, ear infections, or gastroenteritis during the first 8 years of life varies according to age at initiation and type of group child care (GCC).
Design/Methods: A cohort of 2023 newborns in Quebec, Canada, was followed up prospectively for 8 years.
A total of 61% completed the 8-year study. On a yearly basis, mothers reported the frequency of RTIs, ear infections, and gastroenteritis in the past 3 months from age 1.5 years through 8.0 years of age. Child care was split into 3 categories: home care, "large" GCC (institution-based care), and "small" GCC (home-based care for 3 to 8 children).
Results: Compared with home care, children who started large GCC in early preschool (1.5 to 2.5 years) had higher rates of RTIs (incidence rate ratio [IRR], 1.61) and ear infections (IRR, 1.62) during that time, no difference during late preschool years (3.5 to 4.5 years), and fewer RTIs (IRR, 0.79) and ear infections (IRR, 0.57) during the elementary school years (5 to 8 years). Children who started large GCC in late preschool had more RTIs (IRR, 1.47) and ear infections (IRR, 2.36) at that time but were no different by elementary school. Children who started small GCC in early preschool years had more ear infections (IRR, 1.47) in the late preschool period but were also no different by elementary school. Gastroenteritis rates in GCC did not differ from home care at any time period. When the entire study period was examined (1.5 years to 8.0 years), there were no differences in RTIs, ear infections, or gastroenteritis between those in GCC or home care.
When compared to home care, early enrollment in large GCC led to more RTIs and ear infections initially but fewer of these infections at elementary school age. Those who started large GCC in late preschool age also had more infections initially, but they did not receive the protective effect during elementary school age. Furthermore, early enrollment in small GCC led to more ear infections initially but no reductions in infections at elementary school age. These findings suggest that enhanced immunity in elementary school age depends upon exposure to many children (large GCC) and initiation of GCC at an early age (before 2.5 years).
Reviewer's Comments: This study can help pediatricians to assuage parents' guilt about starting large group day care for their young children. These kids may suffer from more infections initially, but they will have fewer infections at elementary school age. Also, the increased rates of infection incurred at the start of GCC were not dramatically higher (with IRRs between 1.47 and 1.62). The study did not examine the impact of GCC prior to 1. In patients with coronary disease, lowering blood pressure too much may increase future ischemic events.
Background: For the general population, a strategy of "lower is better" prevails in the treatment of hypertension. However, there are many who believe in a J-or U-shaped curve with higher event rates at both very low and very high blood pressure (BP) in patients with coronary disease.
Objective: To look at the PROVE IT-TIMI 22 subjects in an effort to determine optimal BP following acute coronary syndromes (ACSs).
Participants/Methods: 4162 patients with ACS in the preceding 10 days were randomized to pravastatin 40 mg or atorvastatin 80 mg per day. The primary outcome was a composite of time to death, myocardial infarction (MI), unstable angina hospitalization, revascularization, and stroke. The secondary outcome was coronary death, MI, or revascularization after 30 days. Tertiary outcomes consisted of all-cause mortality, coronary death, and nonfatal MI considered separately.
Results:
The primary outcome was reached in 1000 subjects (24%). The relationship between systolic BP and outcome was J-shaped. Compared with the reference group (systolic 130 to 140 mm Hg), risk increased 4.9 times among those with systolic BP ≤100, while risk increased 1.2-fold with systolic BP >160. Diastolic BP also followed a J-shaped relationship with the primary outcome. Compared with the reference group (diastolic 81 to 90 mm Hg), risk increased 3.7 times among those with diastolic BP ≤60, while risk increased 2.1 times with diastolic BP >100. This J-shaped relationship was more pronounced with follow-up than with baseline BP. A Jshaped relationship was also found for the secondary outcome as well as for cardiovascular mortality and for nonfatal MI.
Conclusions:
In this population of ACS patients, there was a J-shaped relationship between BP and cardiovascular events. This was true for systolic as well as diastolic BP. Exponential increases in such events were seen at both high and low BP values. BP <110/70 was associated with increased risk of events and may be too low in patients with coronary disease.
Reviewer's Comments: As the authors point out, the controversy over the existence of a J-shaped relationship between BP and cardiovascular events has existed for many years. There is persistent concern that lowering BP too far, particularly diastolic BP, in the presence of coronary disease may lead to increased coronary ischemic events. Such a J-shaped relationship has been observed in many studies of hypertension involving coronary disease patients, but is less consistently seen in primary prevention studies involving patients without cardiovascular disease at baseline. It is important to note that observation of a statistically significant relationship does not prove causality. It could be that patients with a poor prognosis mount a lower blood pressure, or it could be that the low BP itself causes the events associated with a poor prognosis. As in the case of blood sugar, "tight control" may not always be best, particularly in patients with significant comorbidities. (Reviewer-Gregg S. Pressman, MD).
